PREVENT Preclinical Efficacy & Endpoint Biomarkers
Award Notice Posted
- Solicitation number
- 75N91023R00024
- Agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Awarded
- to The Institute For Cancer Research
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- 75N91024D00003 Federal IDV award
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Notice details come from SAM.gov. Updated .
About this opportunity
The Institute for Cancer Research has been awarded a PREVENT Preclinical Efficacy & Intermediate Endpoint Biomarkers IDIQ contract by the National Cancer Institute, part of the National Institutes of Health within the Department of Health and Human Services. This contract, valued at $149,995,000, will support the PREVENT Cancer Preclinical Drug Development Program through the provision of preclinical efficacy and intermediate endpoint biomarkers in an indefinite-delivery/indefinite-quantity arrangement.
Notice text
Preclinical Efficacy & Intermediate Endpoint Biomarkers IDIQ contract in support of the PREVENT Cancer Preclinical Drug Development Program Awarded contract 75N91024D00003 to THE INSTITUTE FOR CANCER RESEARCH for 149995000 on 2024-01-24.
Notice history
| Notice | Type | Posted |
|---|---|---|
| PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers, Preclinical Services for cGMP Biopharmaceutical Product Development and Manufacturing, and Toxicology and Pharmacology Testing | Award Notice | |
| PREVENT Preclinical Efficacy & Endpoint Biomarkers | Award Notice | |
| PREVENT Preclinical Efficacy & Endpoint Biomarkers | Award Notice | |
| This notice | Award Notice | |
| Prevent IDIQ mato RFP | Solicitation | |
| Prevent IDIQ mato RFP | Pre-Solicitation |
6 of 13 notices listed here. See the rest on GovTribe.
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity